- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The weak companies could be clobbered.
Regulators say company squelched competing drug for infant seizures.
Drugmaker faced antitrust charges over 2013 Synacthen purchase.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.